Which has preferable valuation & earnings, DCGO or XGN?

Exagen has lower revenue, but higher earnings than DocGo. Exagen is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $301.71M 0.19 -$182.40M -$1.91 N/A Exagen $66.57M 1.74 -$19.95M -$0.89 N/A

Is DCGO or XGN more profitable?

Exagen has a net margin of -29.49% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% Exagen -29.49% -94.37% -28.96%

Do analysts recommend BNR or DCGO?

DocGo has a consensus price target of $2.38, indicating a potential upside of 298.82%. Given DocGo's stronger consensus rating and higher possible upside, analysts plainly believe DocGo is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media prefer BNR or DCGO?

In the previous week, Burning Rock Biotech had 14 more articles in the media than DocGo. MarketBeat recorded 16 mentions for Burning Rock Biotech and 2 mentions for DocGo. Burning Rock Biotech's average media sentiment score of 1.01 beat DocGo's score of 0.40 indicating that Burning Rock Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Burning Rock Biotech 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DocGo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, DCGO or PIII?

P3 Health Partners has higher revenue and earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $301.71M 0.19 -$182.40M -$1.91 N/A P3 Health Partners $1.47B 0.05 -$147.95M -$38.60 N/A

Is DCGO or PIII more profitable?

P3 Health Partners has a net margin of -8.57% compared to DocGo's net margin of -62.23%. P3 Health Partners' return on equity of 0.00% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% P3 Health Partners -8.57% N/A -19.99%

Does the media refer more to DCGO or PIII?

In the previous week, DocGo had 1 more articles in the media than P3 Health Partners. MarketBeat recorded 2 mentions for DocGo and 1 mentions for P3 Health Partners. DocGo's average media sentiment score of 0.40 beat P3 Health Partners' score of 0.00 indicating that DocGo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral P3 Health Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DCGO or SERA more profitable?

DocGo has a net margin of -62.23% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% Sera Prognostics -56,385.97% -41.02% -30.95%

Does the media refer more to DCGO or SERA?

In the previous week, DocGo had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 2 mentions for DocGo and 1 mentions for Sera Prognostics. DocGo's average media sentiment score of 0.40 beat Sera Prognostics' score of 0.00 indicating that DocGo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

DocGo (DCGO) Competitors

$0.60 +0.01 (+1.29%)

Closing price 04:00 PM Eastern

Extended Trading

$0.59 0.00 (-0.59%)

As of 05:14 PM Eastern

Compare

DCGO vs. XGN, PARK, BNR, PIII, and SERA

Should you buy DocGo stock or one of its competitors? MarketBeat compares DocGo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DocGo include Exagen (XGN), Park Dental Partners (PARK), Burning Rock Biotech (BNR), P3 Health Partners (PIII), and Sera Prognostics (SERA). These companies are all part of the "healthcare" industry.

How does DocGo compare to Exagen?

DocGo (NASDAQ:DCGO) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Exagen has a net margin of -29.49% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Exagen	-29.49%	-94.37%	-28.96%

DocGo presently has a consensus target price of $2.38, suggesting a potential upside of 298.82%. Exagen has a consensus target price of $9.11, suggesting a potential upside of 89.81%. Given DocGo's higher possible upside, analysts clearly believe DocGo is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Exagen has lower revenue, but higher earnings than DocGo. Exagen is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$301.71M	0.19	-$182.40M	-$1.91	N/A
Exagen	$66.57M	1.74	-$19.95M	-$0.89	N/A

56.4% of DocGo shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 3.8% of DocGo shares are held by insiders. Comparatively, 10.4% of Exagen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

DocGo has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Exagen has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market.

In the previous week, DocGo had 2 more articles in the media than Exagen. MarketBeat recorded 2 mentions for DocGo and 0 mentions for Exagen. DocGo's average media sentiment score of 0.40 beat Exagen's score of 0.00 indicating that DocGo is being referred to more favorably in the media.

Company	Overall Sentiment
DocGo	Neutral
Exagen	Neutral

Summary

Exagen beats DocGo on 11 of the 17 factors compared between the two stocks.

How does DocGo compare to Park Dental Partners?

DocGo (NASDAQ:DCGO) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

56.4% of DocGo shares are held by institutional investors. 3.8% of DocGo shares are held by company insiders. Comparatively, 10.6% of Park Dental Partners shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Park Dental Partners has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$301.71M	0.19	-$182.40M	-$1.91	N/A
Park Dental Partners	$244.49M	0.39	-$360K	$0.74	28.35

In the previous week, DocGo had 2 more articles in the media than Park Dental Partners. MarketBeat recorded 2 mentions for DocGo and 0 mentions for Park Dental Partners. DocGo's average media sentiment score of 0.40 beat Park Dental Partners' score of 0.00 indicating that DocGo is being referred to more favorably in the media.

Company	Overall Sentiment
DocGo	Neutral
Park Dental Partners	Neutral

DocGo presently has a consensus target price of $2.38, suggesting a potential upside of 298.82%. Park Dental Partners has a consensus target price of $21.75, suggesting a potential upside of 3.67%. Given DocGo's higher probable upside, equities research analysts clearly believe DocGo is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75

Park Dental Partners has a net margin of 0.00% compared to DocGo's net margin of -62.23%. Park Dental Partners' return on equity of 0.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Park Dental Partners	N/A	N/A	N/A

Summary

Park Dental Partners beats DocGo on 10 of the 16 factors compared between the two stocks.

How does DocGo compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

DocGo has a consensus price target of $2.38, indicating a potential upside of 298.82%. Given DocGo's stronger consensus rating and higher possible upside, analysts plainly believe DocGo is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Burning Rock Biotech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, DocGo has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 3.8% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Burning Rock Biotech had 14 more articles in the media than DocGo. MarketBeat recorded 16 mentions for Burning Rock Biotech and 2 mentions for DocGo. Burning Rock Biotech's average media sentiment score of 1.01 beat DocGo's score of 0.40 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Burning Rock Biotech	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DocGo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Burning Rock Biotech has higher earnings, but lower revenue than DocGo. Burning Rock Biotech is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.46	-$7.92M	-$0.82	N/A
DocGo	$301.71M	0.19	-$182.40M	-$1.91	N/A

Burning Rock Biotech has a net margin of -11.57% compared to DocGo's net margin of -62.23%. Burning Rock Biotech's return on equity of -10.98% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
DocGo	-62.23%	-44.09%	-29.14%

Summary

Burning Rock Biotech beats DocGo on 10 of the 16 factors compared between the two stocks.

How does DocGo compare to P3 Health Partners?

DocGo (NASDAQ:DCGO) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

P3 Health Partners has a net margin of -8.57% compared to DocGo's net margin of -62.23%. P3 Health Partners' return on equity of 0.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
P3 Health Partners	-8.57%	N/A	-19.99%

56.4% of DocGo shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 3.8% of DocGo shares are held by insiders. Comparatively, 10.9% of P3 Health Partners shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

P3 Health Partners has higher revenue and earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$301.71M	0.19	-$182.40M	-$1.91	N/A
P3 Health Partners	$1.47B	0.05	-$147.95M	-$38.60	N/A

DocGo has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market.

In the previous week, DocGo had 1 more articles in the media than P3 Health Partners. MarketBeat recorded 2 mentions for DocGo and 1 mentions for P3 Health Partners. DocGo's average media sentiment score of 0.40 beat P3 Health Partners' score of 0.00 indicating that DocGo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
P3 Health Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DocGo currently has a consensus target price of $2.38, suggesting a potential upside of 298.82%. P3 Health Partners has a consensus target price of $14.00, suggesting a potential upside of 32.95%. Given DocGo's stronger consensus rating and higher probable upside, research analysts clearly believe DocGo is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

DocGo and P3 Health Partners tied by winning 8 of the 16 factors compared between the two stocks.

How does DocGo compare to Sera Prognostics?

DocGo (NASDAQ:DCGO) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, DocGo had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 2 mentions for DocGo and 1 mentions for Sera Prognostics. DocGo's average media sentiment score of 0.40 beat Sera Prognostics' score of 0.00 indicating that DocGo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DocGo presently has a consensus target price of $2.38, indicating a potential upside of 298.82%. Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 173.63%. Given DocGo's higher possible upside, research analysts clearly believe DocGo is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Sera Prognostics has lower revenue, but higher earnings than DocGo. Sera Prognostics is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$301.71M	0.19	-$182.40M	-$1.91	N/A
Sera Prognostics	$80K	983.90	-$31.93M	-$0.65	N/A

56.4% of DocGo shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 3.8% of DocGo shares are held by insiders. Comparatively, 11.3% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

DocGo has a net margin of -62.23% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Sera Prognostics	-56,385.97%	-41.02%	-30.95%

DocGo has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Summary

DocGo beats Sera Prognostics on 10 of the 17 factors compared between the two stocks.

Get DocGo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCGO vs. The Competition

Export

Metric	DocGo	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$58.81M	$9.49B	$6.95B	$12.44B
Dividend Yield	N/A	1.62%	2.67%	6.51%
P/E Ratio	-0.31	26.45	27.22	24.45
Price / Sales	0.19	18.04	532.27	95.07
Price / Cash	10.04	15.44	29.65	49.26
Price / Book	0.47	6.22	10.97	6.42
Net Income	-$182.40M	$177.20M	$3.56B	$335.85M
7 Day Performance	15.38%	3.34%	1.77%	-0.48%
1 Month Performance	6.49%	10.45%	6.65%	3.39%
1 Year Performance	-60.82%	15.22%	36.06%	24.97%

DocGo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCGO DocGo	2.9695 of 5 stars	$0.60 +1.3%	$2.38 +298.8%	-62.9%	$58.81M	$301.71M	N/A	3,568
XGN Exagen	3.631 of 5 stars	$4.58 -1.3%	$9.11 +98.9%	-34.7%	$110.65M	$66.57M	N/A	220
PARK Park Dental Partners	2.3429 of 5 stars	$19.49 +6.8%	$21.75 +11.6%	N/A	$88.00M	$248.15M	N/A	1,208	Positive News
BNR Burning Rock Biotech	1.8389 of 5 stars	$8.23 +3.5%	N/A	+206.1%	$86.57M	$77.16M	N/A	1,390	Positive News Gap Up
PIII P3 Health Partners	2.4437 of 5 stars	$11.31 +5.9%	$14.00 +23.8%	+61.7%	$81.88M	$1.46B	N/A	500	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCGO) was last updated on 7/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DocGo (DCGO) Competitors

DCGO vs. XGN, PARK, BNR, PIII, and SERA

How does DocGo compare to Exagen?

Summary

How does DocGo compare to Park Dental Partners?

Summary

How does DocGo compare to Burning Rock Biotech?

Summary

How does DocGo compare to P3 Health Partners?

Summary

How does DocGo compare to Sera Prognostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCGO vs. The Competition

DocGo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DocGo (DCGO) Competitors

DCGO vs. XGN, PARK, BNR, PIII, and SERA

How does DocGo compare to Exagen?

Is DCGO or XGN more profitable?

Do analysts prefer DCGO or XGN?

Which has preferable valuation & earnings, DCGO or XGN?

Do institutionals and insiders believe in DCGO or XGN?

Which has more volatility & risk, DCGO or XGN?

Does the media refer more to DCGO or XGN?

Summary

How does DocGo compare to Park Dental Partners?

Do insiders & institutionals believe in DCGO or PARK?

Which has better earnings & valuation, DCGO or PARK?

Does the media refer more to DCGO or PARK?

Do analysts prefer DCGO or PARK?

Is DCGO or PARK more profitable?

Summary

How does DocGo compare to Burning Rock Biotech?

Do analysts recommend BNR or DCGO?

Which has more volatility and risk, BNR or DCGO?

Do institutionals and insiders believe in BNR or DCGO?

Does the media prefer BNR or DCGO?

Which has preferable valuation and earnings, BNR or DCGO?

Is BNR or DCGO more profitable?

Summary

How does DocGo compare to P3 Health Partners?

Is DCGO or PIII more profitable?

Do institutionals and insiders hold more shares of DCGO or PIII?

Which has stronger valuation & earnings, DCGO or PIII?

Which has more risk and volatility, DCGO or PIII?

Does the media refer more to DCGO or PIII?

Do analysts recommend DCGO or PIII?

Summary

How does DocGo compare to Sera Prognostics?

Does the media refer more to DCGO or SERA?

Do analysts rate DCGO or SERA?

Which has stronger valuation & earnings, DCGO or SERA?

Do insiders and institutionals have more ownership in DCGO or SERA?

Is DCGO or SERA more profitable?

Which has more volatility & risk, DCGO or SERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCGO vs. The Competition

DocGo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools